Cadrenal Therapeutics

CVKD

Market cap $21.1M

PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D.

PONTE VEDRA, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced its Chairman and Chief Executive Officer, Quang X. Pham, received the prestigious BioFlorida, Inc. “Executive of the Year Award,” at the recently held Florida Innovation Conference, powered by BioFlorida, in Orlando.

PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian.

Valuation

Valuation

PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.

Acquisition significantly enhances the Company's pipeline by adding novel assets in acute and chronic anticoagulation settings Company is strategically poised to deliver differentiated therapeutics across the spectrum of cardiovascular thrombotic risk PONTE VEDRA, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced the acquisition of the assets of eXIthera Pharmaceuticals (“eXIthera”), including its proprietary portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors.

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal Therapeutics reports on Second Quarter 2025 financial results and provides corporate update on strategic clinical trial plans.

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #AFib--Cadrenal announces clinical trial initiation plans for tecarfarin in patients with end-stage kidney disease (ESKD) who are transitioning to dialysis.

PONTE VEDRA, Fla.--(BUSINESS WIRE)---- $CVKD #cadrenaltherapeutics--Cadrenal Therapeutics highlights new research on the economic and medical burden associated with oral anticoagulation for LVAD patients.